PMID: 9549636Apr 29, 1998Paper

Single- and multiple-dose pharmacokinetics of riluzole in white subjects

Journal of Clinical Pharmacology
A Le LibouxG Montay

Abstract

Riluzole is a novel neuroprotective agent that has been developed for the treatment of amyotrophic lateral sclerosis. A series of studies was undertaken to establish its pharmacokinetics on single- and multiple-dose administration in young white male volunteers. The mean absolute oral bioavailability of riluzole (50-mg tablet) was approximately 60%. Maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) values were linearly related to dose for the range studied. Cmax occurred at 1.0 hour to 1.5 hours after administration. Plasma elimination half-life appeared to be independent of dose. After repeated administration of 100 mg riluzole for 10 days, some intraindividual variability in bioavailability was seen. A high-fat meal significantly reduced the rate (tmax = 2 hours compared with 0.8 hours; Cmax = 216 ng.mL-1 compared to 387 ng.mL-1) and extent of absorption (AUC = 1,047 ng.hr.mL-1 versus 1,269 ng.hr.mL-1). With multiple-dose administration, riluzole showed dose-related absorption, although the terminal plasma half-life was prolonged slightly. Steady-state plasma concentrations were achieved within 5 days. Steady-state trough plasma concentrations were significantly higher with a 75-mg dose twi...Continue Reading

References

Aug 1, 1972·Journal of Pharmaceutical Sciences·W J Westlake
Jul 1, 1982·Journal of Clinical Pharmacology·K W HallA R DiSanto
Oct 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·K K Chan, M Gibaldi
Jun 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·H Boxenbaum
Apr 14, 1994·Neuroreport·P CouratierJ Hugon
Mar 3, 1994·The New England Journal of Medicine·G BensimonV Meininger
Jul 1, 1993·Neurology·S P RingelF Ziter

❮ Previous
Next ❯

Citations

Apr 6, 2004·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Milena ColovicSilvio Caccia
Oct 26, 2001·Journal of the Neurological Sciences·G J GroeneveldL H van den Berg
Feb 22, 2002·Alimentary Pharmacology & Therapeutics·D P HirschG E E Boeckxstaens
Oct 13, 2000·The European Journal of Neuroscience·A Urbani, O Belluzzi
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Dec 21, 2010·Experimental Neurology·Marin Manuel, C J Heckman
Nov 27, 2007·European Journal of Pharmacology·Elena FumagalliTiziana Mennini
Sep 21, 2004·Journal of Neuroscience Research·Federica AlboCristina Zona
Feb 3, 2011·British Journal of Clinical Pharmacology·Chadi AbbaraBertrand Diquet
Jul 5, 2013·Journal of Pharmacological Sciences·Sachie Sasaki-HamadaJun-Ichiro Oka
Aug 30, 2006·Human & Experimental Toxicology·W C ChenC R Jan
May 6, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Narihito NagoshiMichael G Fehlings
Oct 24, 2003·Journal of Neurophysiology·Nikolai I KononenkoF Edward Dudek
Sep 19, 2012·Journal of Neurosurgery. Spine·Diana S L ChowRobert G Grossman
Mar 9, 2005·British Journal of Clinical Pharmacology·H J M van KanH J Guchelaar
Jun 17, 2006·Journal of Applied Physiology·Edward Vincent S Faustino, David F Donnelly
Aug 12, 2006·Journal of Applied Physiology·Edward Vincent S Faustino, David F Donnelly
Jul 4, 2006·The Journal of Pharmacology and Experimental Therapeutics·Hye Sook AhnSang June Hahn
Oct 19, 2017·Journal of Clinical Psychopharmacology·Paul GrantSusan Swedo
Feb 11, 2020·Toxicological Sciences : an Official Journal of the Society of Toxicology·Diane M LongoIrfan A Qureshi
Aug 28, 2020·Neurodegenerative Disease Management·Yuji Saitoh, Yuji Takahashi
Mar 17, 2021·European Journal of Pharmacology·David O Pacheco-RojasTania Ferrer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.